GlassScriptPrepare for your visit
Martin Majer
Hematology & Oncology · Oroville, CA · NPI 1376749234
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$7,219.09
in general payments reported to CMS, 2019-2025 · $3,271 in 2025
The $3,271 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Who reported paying
General payments only, top 6 by amount.
- Novartis Pharmaceuticals Corporation $1,667.22
- Astrazeneca Pharmaceuticals LP $643.58
- E.R. Squibb & Sons, L.L.C. $432.83
- Abbvie INC. $382.27
- Incyte Corporation $345.54
- Merck Sharp & Dohme LLC $326.07
Drugs and devices associated with these payments
Kisqali Imfinzi Lenvima Jakafi Epkinly Keytruda Jemperli Braftovi Mektovi Reblozyl Nubeqa Pomalyst
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Martin Majer listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/289710/martin-majer